Value through Innovation27 July 2016

What is a lay summary?

Clinical Study Results

  • Volasertib - Urologic Neoplasms
    Clinical Study Number 1230.2
    Study Indication Urologic Neoplasms
    Product Volasertib
    Generic Name Volasertib
    Lab Code BI 6727
    Clinical Phase II
    Study Title

    An open-label, single-arm, Phase II trial of intravenous volasertib (BI 6727) in patients with locally advanced, metastatic or recurrent urothelial cancer of the bladder, renal pelvis, or ureters after failure of prior chemotherapy

    Study Document
    Trial synopsis 1230.2 english